Priya Karmali

Company: Capstan Therapeutics

Job title: Chief Technology Officer

Seminars:

In Vivo Engineering of Cells Using Targeted Lipid Nanoparticles 2:45 pm

Capstan’s novel targeted LNP (tLNP) platform purpose-built for preferential delivery of RNA to target cells tLNP platform enables two distinct approaches in vivo: direct engineering of immune cells and targeting pathogenic cells Versatility of this non-viral, redosable and scalable platform allows for in vivo RNA-based therapies across broad range of diseasesRead more

day: Conference Day Two